Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells.

Avanzini MA, Abbonante V, Catarsi P, Dambruoso I, Mantelli M, Poletto V, Lenta E, Guglielmelli P, Croce S, Cobianchi L, Jemos B, Campanelli R, Bonetti E, Di Buduo CA, Salmoiraghi S, Villani L, Massa M, Boni M, Zappatore R, Iurlo A, Rambaldi A, Vannucchi AM, Bernasconi P, Balduini A, Barosi G, Rosti V; AGIMM Investigators.

Am J Hematol. 2018 May;93(5):615-622. doi: 10.1002/ajh.25047. Epub 2018 Feb 8.

PMID:
29359451
2.

Acetylcholine induces intracellular Ca2+ oscillations and nitric oxide release in mouse brain endothelial cells.

Zuccolo E, Lim D, Kheder DA, Perna A, Catarsi P, Botta L, Rosti V, Riboni L, Sancini G, Tanzi F, D'Angelo E, Guerra G, Moccia F.

Cell Calcium. 2017 Sep;66:33-47. doi: 10.1016/j.ceca.2017.06.003. Epub 2017 Jun 12.

PMID:
28807148
3.

Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease.

Barosi G, Massa M, Campanelli R, Fois G, Catarsi P, Viarengo G, Villani L, Poletto V, Bosoni T, Magrini U, Gale RP, Rosti V.

Leuk Res. 2017 Sep;60:18-23. doi: 10.1016/j.leukres.2017.06.004. Epub 2017 Jun 7.

PMID:
28622624
4.

Arachidonic acid-evoked Ca2+ signals promote nitric oxide release and proliferation in human endothelial colony forming cells.

Zuccolo E, Dragoni S, Poletto V, Catarsi P, Guido D, Rappa A, Reforgiato M, Lodola F, Lim D, Rosti V, Guerra G, Moccia F.

Vascul Pharmacol. 2016 Dec;87:159-171. doi: 10.1016/j.vph.2016.09.005. Epub 2016 Sep 12.

PMID:
27634591
5.

Reduced frequency of circulating CD4+CD25brightCD127lowFOXP3+ regulatory T cells in primary myelofibrosis.

Massa M, Campanelli R, Fois G, Villani L, Bonetti E, Catarsi P, Poletto V, Viarengo G, De Amici M, Rosti V, Gale RP, Barosi G.

Blood. 2016 Sep 22;128(12):1660-2. doi: 10.1182/blood-2016-03-704577. Epub 2016 Aug 16. No abstract available.

6.

Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis.

Campanelli R, Fois G, Catarsi P, Poletto V, Villani L, Erba BG, Maddaluno L, Jemos B, Salmoiraghi S, Guglielmelli P, Abbonante V, Di Buduo CA, Balduini A, Iurlo A, Barosi G, Rosti V, Massa M; AGIMM Investigators.

PLoS One. 2016 Jun 9;11(6):e0156990. doi: 10.1371/journal.pone.0156990. eCollection 2016.

7.

Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.

Rosti V, Campanelli R, Massa M, Viarengo G, Villani L, Poletto V, Bonetti E, Catarsi P, Magrini U, Grolla AA, Travelli C, Genazzani AA, Barosi G.

Am J Hematol. 2016 Jul;91(7):709-13. doi: 10.1002/ajh.24388. Epub 2016 May 26.

8.

JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy.

Barosi G, Klersy C, Villani L, Bonetti E, Catarsi P, Poletto V, Campanelli R, Impera S, Latagliata R, Viarengo G, Carolei A, Massa M, Musso M, Crescimanno A, Gale RP, Rosti V.

Leukemia. 2016 Aug;30(8):1772-5. doi: 10.1038/leu.2016.45. Epub 2016 Feb 29. No abstract available.

PMID:
26975727
9.

Altered fibronectin expression and deposition by myeloproliferative neoplasm-derived mesenchymal stromal cells.

Abbonante V, Gruppi C, Catarsi P, Avanzini MA, Tira ME, Barosi G, Rosti V, Balduini A.

Br J Haematol. 2016 Jan;172(1):140-4. doi: 10.1111/bjh.13471. Epub 2015 May 5. No abstract available.

PMID:
25940987
10.

JAK2 exon 14 skipping in patients with primary myelofibrosis: a minor splice variant modulated by the JAK2-V617F allele burden.

Catarsi P, Rosti V, Morreale G, Poletto V, Villani L, Bertorelli R, Pedrazzini M, Zorzetto M, Barosi G; AGIMM investigators.

PLoS One. 2015 Jan 24;10(1):e0116636. doi: 10.1371/journal.pone.0116636. eCollection 2015.

11.

Functional and genetic aberrations of in vitro-cultured marrow-derived mesenchymal stromal cells of patients with classical Philadelphia-negative myeloproliferative neoplasms.

Avanzini MA, Bernardo ME, Novara F, Mantelli M, Poletto V, Villani L, Lenta E, Ingo DM, Achille V, Bonetti E, Massa M, Campanelli R, Fois G, Catarsi P, Gale RP, Moretta A, Aronica A, Maccario R, Acquafredda G, Lisini D, Zecca M, Zuffardi O, Locatelli F, Barosi G, Rosti V; AGIMM Investigators.

Leukemia. 2014 Aug;28(8):1742-5. doi: 10.1038/leu.2014.97. Epub 2014 Mar 12. No abstract available.

PMID:
24618733
12.

No association between the XPD Lys751Gln (rs13181) polymorphism and disease phenotype or leukemic transformation in primary myelofibrosis.

Poletto V, Villani L, Catarsi P, Campanelli R, Massa M, Vannucchi AM, Rosti V, Barosi G.

Haematologica. 2013 Aug;98(8):e83-4. doi: 10.3324/haematol.2013.086496. Epub 2013 May 28. No abstract available.

13.

JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis.

Barosi G, Poletto V, Massa M, Campanelli R, Villani L, Bonetti E, Viarengo G, Catarsi P, Klersy C, Rosti V.

PLoS One. 2013;8(3):e59791. doi: 10.1371/journal.pone.0059791. Epub 2013 Mar 26.

14.

Involvement of TGFβ1 in autocrine regulation of proplatelet formation in healthy subjects and patients with primary myelofibrosis.

Badalucco S, Di Buduo CA, Campanelli R, Pallotta I, Catarsi P, Rosti V, Kaplan DL, Barosi G, Massa M, Balduini A.

Haematologica. 2013 Apr;98(4):514-7. doi: 10.3324/haematol.2012.076752. Epub 2013 Feb 12.

15.

Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation.

Rosti V, Villani L, Riboni R, Poletto V, Bonetti E, Tozzi L, Bergamaschi G, Catarsi P, Dallera E, Novara F, Massa M, Campanelli R, Fois G, Peruzzi B, Lucioni M, Guglielmelli P, Pancrazzi A, Fiandrino G, Zuffardi O, Magrini U, Paulli M, Vannucchi AM, Barosi G; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators.

Blood. 2013 Jan 10;121(2):360-8. doi: 10.1182/blood-2012-01-404889. Epub 2012 Nov 5.

16.

A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation.

Poletto V, Rosti V, Villani L, Catarsi P, Carolei A, Campanelli R, Massa M, Martinetti M, Viarengo G, Malovini A, Migliaccio AR, Barosi G.

Blood. 2012 Oct 11;120(15):3112-7. doi: 10.1182/blood-2012-05-433466. Epub 2012 Aug 9.

17.

Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis.

Barosi G, Rosti V, Bonetti E, Campanelli R, Carolei A, Catarsi P, Isgrò AM, Lupo L, Massa M, Poletto V, Viarengo G, Villani L, Magrini U.

PLoS One. 2012;7(4):e35631. doi: 10.1371/journal.pone.0035631. Epub 2012 Apr 20.

18.

JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms.

Villani L, Bergamaschi G, Primignani M, Rosti V, Carolei A, Poletto V, Catarsi P, Spolverini A, Vannucchi AM, Barosi G.

Leuk Res. 2012 Jan;36(1):e7-9. doi: 10.1016/j.leukres.2011.08.008. Epub 2011 Sep 3. No abstract available.

PMID:
21890200
19.

Impact of erythropoietin on the effects of irradiation under hypoxia.

Lo Nigro C, Maffi M, Fischel JL, Monteverde M, Catarsi P, Tonissi F, Lattanzio L, Riba M, Etienne-Grimaldi MC, Formento P, Milano G, Merlano M.

J Cancer Res Clin Oncol. 2009 Nov;135(11):1615-23. doi: 10.1007/s00432-009-0609-1. Epub 2009 Jun 5.

PMID:
19499245
20.

Cyclosporin and organ specific toxicity: clinical aspects, pharmacogenetics and perspectives.

Magnasco A, Rossi A, Catarsi P, Gusmano R, Ginevri F, Perfumo F, Ghiggeri GM.

Curr Clin Pharmacol. 2008 Sep;3(3):166-73. Review.

PMID:
18781903
21.

Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin.

Marimpietri D, Nico B, Vacca A, Mangieri D, Catarsi P, Ponzoni M, Ribatti D.

Oncogene. 2005 Oct 13;24(45):6785-95.

PMID:
16007159
22.

Angiotensin-converting enzyme (ACE) haplotypes and cyclosporine A (CsA) response: a model of the complex relationship between ACE quantitative trait locus and pathological phenotypes.

Catarsi P, Ravazzolo R, Emma F, Fruci D, Finos L, Frau A, Morreale G, Carrea A, Ghiggeri GM.

Hum Mol Genet. 2005 Aug 15;14(16):2357-67. Epub 2005 Jul 7.

PMID:
16002416
23.

Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study.

Ghiggeri GM, Catarsi P, Scolari F, Caridi G, Bertelli R, Carrea A, Sanna-Cherchi S, Emma F, Allegri L, Cancarini G, Rizzoni GF, Perfumo F.

Clin Ther. 2004 Sep;26(9):1411-8.

PMID:
15531003
24.

Polymorphisms in the osteopontin promoter affect its transcriptional activity.

Giacopelli F, Marciano R, Pistorio A, Catarsi P, Canini S, Karsenty G, Ravazzolo R.

Physiol Genomics. 2004 Dec 15;20(1):87-96. Epub 2004 Oct 12.

PMID:
15479859
25.

Apolipoprotein E in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.

Bruschi M, Catarsi P, Candiano G, Rastaldi MP, Musante L, Scolari F, Artero M, Carraro M, Carrea A, Caridi G, Zennaro C, Sanna-Cherchi S, Viola FB, Ferrario F, Perfumo F, Ghiggeri GM.

Kidney Int. 2003 Feb;63(2):686-95.

26.

Prevalence, genetics, and clinical features of patients carrying podocin mutations in steroid-resistant nonfamilial focal segmental glomerulosclerosis.

Caridi G, Bertelli R, Carrea A, Di Duca M, Catarsi P, Artero M, Carraro M, Zennaro C, Candiano G, Musante L, Seri M, Ginevri F, Perfumo F, Ghiggeri GM.

J Am Soc Nephrol. 2001 Dec;12(12):2742-6.

Supplemental Content

Loading ...
Support Center